KR100768408B1 - 헤르페스 바이러스 주 - Google Patents
헤르페스 바이러스 주 Download PDFInfo
- Publication number
- KR100768408B1 KR100768408B1 KR1020027009412A KR20027009412A KR100768408B1 KR 100768408 B1 KR100768408 B1 KR 100768408B1 KR 1020027009412 A KR1020027009412 A KR 1020027009412A KR 20027009412 A KR20027009412 A KR 20027009412A KR 100768408 B1 KR100768408 B1 KR 100768408B1
- Authority
- KR
- South Korea
- Prior art keywords
- virus
- gene
- strain
- protein
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241001529453 unidentified herpesvirus Species 0.000 title claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 117
- 230000004957 immunoregulator effect Effects 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 102000004127 Cytokines Human genes 0.000 claims abstract description 8
- 108090000695 Cytokines Proteins 0.000 claims abstract description 8
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 5
- 241000700605 Viruses Species 0.000 claims description 111
- 210000004881 tumor cell Anatomy 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 24
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims description 22
- 101150027249 RL1 gene Proteins 0.000 claims description 22
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 16
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 15
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 14
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 210000004443 dendritic cell Anatomy 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 claims description 4
- 108010029697 CD40 Ligand Proteins 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 3
- 108020004440 Thymidine kinase Proteins 0.000 claims description 3
- 101150050057 UL43 gene Proteins 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 230000003915 cell function Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 230000001976 improved effect Effects 0.000 abstract description 8
- 230000000174 oncolytic effect Effects 0.000 abstract description 2
- 101150076998 ICP34.5 gene Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 53
- 206010028980 Neoplasm Diseases 0.000 description 51
- 241000700584 Simplexvirus Species 0.000 description 28
- 201000011510 cancer Diseases 0.000 description 28
- 230000006378 damage Effects 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 230000001093 anti-cancer Effects 0.000 description 10
- 230000035772 mutation Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 230000002101 lytic effect Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000700589 Herpes simplex virus (type 1 / strain 17) Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000004882 non-tumor cell Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 2
- 241000700328 Herpes simplex virus (type 1 / strain F) Species 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101710140363 ICP47 protein Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 102000046157 human CSF2 Human genes 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- -1 B7.2 Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 101001035740 Homo sapiens 3-hydroxyacyl-CoA dehydrogenase type-2 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000700326 Human herpesvirus 1 strain KOS Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241001136036 Murid betaherpesvirus 2 Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710115901 Neurovirulence factor ICP34.5 Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101000746366 Rattus norvegicus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 101150053996 UL47 gene Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/869—Herpesviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0001475.3 | 2000-01-21 | ||
| GB0001475A GB0001475D0 (en) | 2000-01-21 | 2000-01-21 | Virus strains |
| GB0002854.8 | 2000-02-08 | ||
| GB0002854A GB0002854D0 (en) | 2000-02-08 | 2000-02-08 | Virus strains |
| GB0100288A GB0100288D0 (en) | 2001-01-05 | 2001-01-05 | Virus strains |
| GB0100288.0 | 2001-01-05 | ||
| GB0100430A GB0100430D0 (en) | 2001-01-06 | 2001-01-06 | Virus strains |
| GB0100430.8 | 2001-01-06 | ||
| PCT/GB2001/000225 WO2001053505A2 (en) | 2000-01-21 | 2001-01-22 | Herpes virus strains for gene therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030032913A KR20030032913A (ko) | 2003-04-26 |
| KR100768408B1 true KR100768408B1 (ko) | 2007-10-18 |
Family
ID=27447756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027009412A Expired - Lifetime KR100768408B1 (ko) | 2000-01-21 | 2001-01-22 | 헤르페스 바이러스 주 |
| KR1020027009410A Expired - Lifetime KR100802403B1 (ko) | 2000-01-21 | 2001-01-22 | 바이러스 주 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027009410A Expired - Lifetime KR100802403B1 (ko) | 2000-01-21 | 2001-01-22 | 바이러스 주 |
Country Status (22)
| Country | Link |
|---|---|
| US (12) | US7063835B2 (enExample) |
| EP (4) | EP1252322B2 (enExample) |
| JP (6) | JP4810042B2 (enExample) |
| KR (2) | KR100768408B1 (enExample) |
| CN (2) | CN1418255A (enExample) |
| AT (2) | ATE282708T1 (enExample) |
| AU (2) | AU2695101A (enExample) |
| BE (1) | BE2016C033I2 (enExample) |
| BR (3) | BRPI0107736B8 (enExample) |
| CA (2) | CA2398335C (enExample) |
| CY (2) | CY2016020I1 (enExample) |
| DE (2) | DE60115600T2 (enExample) |
| DK (2) | DK1252323T3 (enExample) |
| ES (2) | ES2254359T3 (enExample) |
| FR (1) | FR16C0026I2 (enExample) |
| GB (2) | GB2375113B (enExample) |
| HK (2) | HK1047297B (enExample) |
| IL (4) | IL150678A0 (enExample) |
| LU (2) | LU93100I2 (enExample) |
| NL (2) | NL300820I2 (enExample) |
| PT (1) | PT1252322E (enExample) |
| WO (2) | WO2001053505A2 (enExample) |
Families Citing this family (183)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| BRPI0107736B8 (pt) * | 2000-01-21 | 2021-05-25 | Biovex Ltd | cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1 |
| ES2366608T3 (es) | 2001-03-27 | 2011-10-21 | The General Hospital Corporation | Vectores víricos y su uso en métodos terapéuticos. |
| GB0203285D0 (en) | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
| JP2004099584A (ja) | 2002-05-02 | 2004-04-02 | Keio Gijuku | Ｈｓｖを用いた抗腫瘍剤 |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| US20070003520A1 (en) * | 2003-11-17 | 2007-01-04 | Brown Susanne M | Mutant viruses |
| WO2005094867A1 (ja) * | 2004-03-31 | 2005-10-13 | Tomoki Todo | ウイルス療法の抗癌作用増強剤、癌の予防または治療方法 |
| WO2005099771A2 (en) * | 2004-04-08 | 2005-10-27 | Sangamo Biosciences, Inc. | Methods and compositions for treating neuropathic and neurodegenerative conditions |
| US9273326B2 (en) * | 2004-04-30 | 2016-03-01 | The Brigham And Women's Hospital, Inc. | Tetracycline-regulated gene expression in HSV-1 vectors |
| CN101287834B (zh) * | 2005-05-27 | 2016-11-09 | 圣拉法埃莱医院有限公司 | 基因载体 |
| US20080008686A1 (en) * | 2006-07-10 | 2008-01-10 | The Brigham And Women's Hospital, Inc. | Tetracycline repressor regulated oncolytic viruses |
| US8450106B2 (en) * | 2007-10-17 | 2013-05-28 | The Ohio State University Research Foundation | Oncolytic virus |
| US8313896B2 (en) * | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| CA2689707A1 (en) | 2009-11-16 | 2011-05-16 | Jean-Simon Diallo | Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening |
| SI2516629T1 (sl) | 2009-12-21 | 2016-10-28 | The Brigham And Women's Hospital, Inc. | Cepiva proti virusu herpes simplex |
| CN102146418B (zh) * | 2010-02-09 | 2014-01-15 | 武汉滨会生物科技有限公司 | 重组ⅱ型单纯疱疹病毒载体及其制备方法、重组病毒、药物组合物及应用 |
| JPWO2011101912A1 (ja) * | 2010-02-19 | 2013-06-17 | 国立大学法人 東京大学 | 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物 |
| EP2550298B1 (en) | 2010-03-23 | 2015-07-15 | The Regents of The University of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| WO2012106281A2 (en) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
| RS58146B1 (sr) | 2011-09-08 | 2019-02-28 | Univ New York | Onkolitički herpes simpleks virus i njegova terapeutska upotreba |
| WO2013052915A2 (en) | 2011-10-05 | 2013-04-11 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| WO2013138522A2 (en) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
| US20130280170A1 (en) | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
| EP3473708B1 (en) | 2012-07-24 | 2021-01-27 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| CN114984062A (zh) | 2012-08-30 | 2022-09-02 | 安姆根有限公司 | 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法 |
| US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
| WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
| AU2014290568B2 (en) * | 2013-07-17 | 2020-10-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
| CA2926110C (en) | 2013-10-24 | 2023-05-23 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
| WO2015061386A1 (en) | 2013-10-24 | 2015-04-30 | Amgen Inc. | Injector and method of assembly |
| SI3021859T1 (en) | 2013-10-25 | 2018-04-30 | Psioxus Therapeutics Limited | Oncolytic adenoviruses equipped with heterologous genes |
| WO2015089280A1 (en) | 2013-12-11 | 2015-06-18 | The General Hospital Corporation | Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| EP3785749A1 (en) | 2014-05-07 | 2021-03-03 | Amgen Inc. | Autoinjector with shock reducing elements |
| MX2016015926A (es) | 2014-06-03 | 2017-06-26 | Amgen Inc | Sistema de suministro de farmacos y metodo de uso. |
| CA2964317C (en) | 2014-10-14 | 2021-10-05 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| MX392725B (es) | 2014-10-14 | 2025-03-24 | Amgen Inc | Dispositivo de inyeccion de farmaco con indicadores visuales y audibles. |
| EP3848072A1 (en) | 2014-12-19 | 2021-07-14 | Amgen Inc. | Drug delivery device with proximity sensor |
| JP2017538512A (ja) | 2014-12-19 | 2017-12-28 | アムジエン・インコーポレーテツド | ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置 |
| ES2952055T3 (es) | 2015-01-26 | 2023-10-26 | Ottawa Hospital Res Inst | Composiciones y métodos para la sensibilización viral |
| US10583245B2 (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| JP2018512184A (ja) | 2015-02-27 | 2018-05-17 | アムジエン・インコーポレーテツド | 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置 |
| GB201505860D0 (en) | 2015-04-07 | 2015-05-20 | Agalimmune Ltd | Therapeutic compositions and methods of use for treating cancer |
| WO2016168601A1 (en) | 2015-04-17 | 2016-10-20 | Khalid Shah | Agents, systems and methods for treating cancer |
| KR102854512B1 (ko) * | 2015-04-30 | 2025-09-04 | 아카미스 바이오 리미티드 | B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스 |
| EP3307330B1 (en) | 2015-06-15 | 2021-03-10 | New York University | Method of treatment using oncolytic viruses |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| CN105219738A (zh) * | 2015-09-21 | 2016-01-06 | 北京神源德生物科技有限公司 | 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用 |
| KR20180104597A (ko) | 2015-11-07 | 2018-09-21 | 멀티비르 인코포레이티드 | 암 치료를 위한 종양 억제 유전자 요법 및 면역관문 봉쇄를 포함하는 조성물 |
| WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
| KR20180108590A (ko) | 2015-12-17 | 2018-10-04 | 싸이오서스 테라퓨틱스 엘티디. | 항-tcr-복합체 항체 또는 단편을 암호화하는 바이러스 |
| WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
| EP3400293B2 (en) * | 2016-01-08 | 2023-07-12 | Replimune Limited | Modified oncolytic virus |
| EP4122478A1 (en) | 2016-02-19 | 2023-01-25 | Virogin Biotech Canada Ltd | Compositions and methods of using stat1/3 inhibitors with oncolytic herpes virus |
| US11200298B2 (en) | 2016-03-15 | 2021-12-14 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| WO2017165813A1 (en) | 2016-03-25 | 2017-09-28 | Periphagen, Inc. | High-transducing hsv vectors |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| WO2017189754A1 (en) * | 2016-04-26 | 2017-11-02 | Salk Institute For Biological Studies | Hsv--1 oncolytic virus therapies that specificallyh kill alt dependent cancers |
| WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
| CN109641020B (zh) | 2016-04-29 | 2022-09-02 | 复诺健生物科技加拿大有限公司 | 在癌细胞中具有增强复制的hsv载体 |
| WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| ES2959783T3 (es) | 2016-05-13 | 2024-02-28 | Amgen Inc | Conjunto de cubierta protectora de vial |
| WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| CA3032120A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| ES2972406T3 (es) | 2016-08-01 | 2024-06-12 | Virogin Biotech Canada Ltd | Vectores del virus oncolítico del herpes simple que expresan moléculas estimuladoras del sistema inmunitario |
| US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CN110214025B (zh) | 2016-08-29 | 2024-08-02 | 阿卡米斯生物公司 | 携带双特异性t细胞衔接器的腺病毒 |
| SI3518948T1 (sl) | 2016-10-03 | 2023-09-29 | Ottawa Hospital Research Institute | Kompozicije in metode za povečanje rasti, širjenja ter onkolitične in imunoterapevtske učinkovitosti onkolitičnih RNA-virusov |
| WO2018075447A1 (en) | 2016-10-19 | 2018-04-26 | The Trustees Of Columbia University In The City Of New York | Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma) |
| AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
| AU2017375958A1 (en) | 2016-12-12 | 2019-07-04 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| US11298420B2 (en) | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| CN110650745A (zh) | 2016-12-21 | 2020-01-03 | 曼珍有限责任公司 | 武装复制型溶瘤腺病毒 |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| EP3570917A1 (en) | 2017-01-17 | 2019-11-27 | Amgen Inc. | Injection devices and related methods of use and assembly |
| JP2020507349A (ja) | 2017-02-09 | 2020-03-12 | インダプタ セラピューティクス インコーポレイテッド | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
| MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
| US11369736B2 (en) | 2017-02-17 | 2022-06-28 | Amgen Inc. | Cannula insertion and retraction mechanisms |
| US20200024615A1 (en) * | 2018-07-21 | 2020-01-23 | Richard Postrel | Method for Precise Identification, Targeting and Delivery of Directed Therapies for Destruction of Cancerous Cells |
| EP3592403B1 (en) | 2017-03-06 | 2025-08-20 | Amgen Inc. | Drug delivery device with activation prevention feature |
| MX2019010543A (es) | 2017-03-07 | 2019-10-21 | Amgen Inc | Insercion de agujas por sobrepresion. |
| JP2020509837A (ja) | 2017-03-09 | 2020-04-02 | アムジエン・インコーポレーテツド | 薬剤送達装置のための挿入機構 |
| CA3056392A1 (en) | 2017-03-15 | 2018-09-20 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
| LT3596116T (lt) | 2017-03-16 | 2023-11-10 | Alpine Immune Sciences, Inc. | Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai |
| CA3053812A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
| WO2018170026A2 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| LT3600491T (lt) | 2017-03-28 | 2023-10-10 | Amgen Inc. | Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas |
| EA201992575A1 (ru) | 2017-04-28 | 2020-04-13 | Мерк Шарп И Доум Корп. | Биомаркеры для терапии рака |
| CN106974942A (zh) * | 2017-05-03 | 2017-07-25 | 武汉滨会生物科技股份有限公司 | 重组溶瘤ii型单纯疱疹病毒在制备抗淋巴瘤、食道癌、乳腺癌、胰腺癌药物中的应用 |
| CA3061982A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| EP3634546A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Torque driven drug delivery device |
| CN107354136A (zh) * | 2017-06-15 | 2017-11-17 | 杭州睿可特生物科技有限公司 | 重组单纯疱疹病毒及其制备方法和应用 |
| JP7195276B2 (ja) | 2017-06-22 | 2022-12-23 | アムジエン・インコーポレーテツド | デバイス起動による衝突／衝撃の低減 |
| MX2019015479A (es) | 2017-06-23 | 2020-02-20 | Amgen Inc | Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador. |
| ES2972207T3 (es) | 2017-07-14 | 2024-06-11 | Amgen Inc | Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble |
| US11672733B2 (en) | 2017-07-21 | 2023-06-13 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
| JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
| EP3658203B2 (en) | 2017-07-25 | 2025-10-01 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
| PE20200867A1 (es) | 2017-08-03 | 2020-08-31 | Amgen Inc | Conjugados que comprende una muteina de interleucina 21 y un anticuerpo anti-pd-1 |
| AU2018314227A1 (en) | 2017-08-07 | 2020-02-06 | Amgen Inc. | Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus |
| WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
| US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| JP7150823B2 (ja) | 2017-09-08 | 2022-10-11 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃの阻害剤及びそれを使用する方法 |
| EP3681998A1 (en) | 2017-09-11 | 2020-07-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Tumor organoid model |
| EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
| EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
| EP3694578B1 (en) | 2017-10-09 | 2025-09-24 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| MY203416A (en) | 2017-10-18 | 2024-06-27 | Alpine Immune Sciences Inc | Variant icos ligand immunomodulatory proteins and related compositions and methods |
| SG11202002123XA (en) | 2017-10-27 | 2020-04-29 | Merck Sharp & Dohme | Compositions and methods for treating liver cancer |
| WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
| MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
| ES2994389T3 (en) | 2017-11-06 | 2025-01-23 | Amgen Inc | Drug delivery device with placement and flow sensing |
| CN111225696B (zh) | 2017-11-10 | 2023-07-18 | 安进公司 | 用于药物递送装置的柱塞 |
| CA3079540A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
| AU2018373508A1 (en) | 2017-11-24 | 2020-04-30 | Ottawa Hospital Research Institute | Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses |
| BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
| CA3087273A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
| US11390650B2 (en) | 2018-02-05 | 2022-07-19 | The Brigham And Women's Hospital, Inc. | Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens |
| CN112020510B (zh) | 2018-03-19 | 2024-10-11 | 茂体外尔公司 | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 |
| US11897924B2 (en) * | 2018-03-28 | 2024-02-13 | Bioxodes | Anticoagulant fusion proteins and uses thereof |
| CN112368017A (zh) * | 2018-05-01 | 2021-02-12 | 阿尔伯特爱因斯坦医学院 | HSV-2-DELTA-gD疫苗及其生产和使用方法 |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| KR102662837B1 (ko) | 2018-06-04 | 2024-05-03 | 카리디 바이오테라퓨틱스, 인크. | 바이러스 치료법의 강화를 위한 세포-기반 비히클 |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| CA3142073A1 (en) * | 2018-06-08 | 2019-12-12 | The Board Of Trustees Of University Of Illinois | Recombinant herpes simplex virus for cancer immunotherapy |
| US12054526B2 (en) * | 2018-06-15 | 2024-08-06 | Children's Hospital Medical Center | Polypeptides, nucleic acid molecules, compositions, and related methods |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| US12115360B2 (en) | 2018-07-24 | 2024-10-15 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| CN112351804A (zh) | 2018-07-24 | 2021-02-09 | 安进公司 | 用于施用药物的输送装置 |
| MX2021000748A (es) | 2018-07-24 | 2021-03-26 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
| WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
| CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
| CN109161561A (zh) * | 2018-08-09 | 2019-01-08 | 湖北科技学院 | 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法 |
| US11242528B2 (en) | 2018-08-28 | 2022-02-08 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
| EP3856283A1 (en) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| TWI857975B (zh) | 2018-10-02 | 2024-10-11 | 美商安進公司 | 具有內部力傳遞的用於藥物遞送之注射系統 |
| MX2021003491A (es) | 2018-10-05 | 2021-06-18 | Amgen Inc | Dispositivo de administracion de farmacos con indicador de dosis. |
| EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
| EA202191038A1 (ru) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | Способ платформенной сборки для устройства доставки лекарственного средства |
| US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| EP3873563A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| KR20210091740A (ko) | 2018-11-06 | 2021-07-22 | 카리디 바이오테라퓨틱스, 인크. | 세포-매개된 종양용해 바이러스 요법용 향상된 시스템 |
| CN113891934A (zh) | 2018-11-21 | 2022-01-04 | 因达普塔治疗公司 | 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法 |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| US20220372106A1 (en) | 2018-11-30 | 2022-11-24 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| AU2019414450B2 (en) | 2018-12-27 | 2025-07-03 | Amgen Inc. | Lyophilized virus formulations |
| WO2020163703A1 (en) * | 2019-02-08 | 2020-08-13 | Krystal Biotech, Inc. | Compositions and methods for delivering cftr polypeptides |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| AU2020229875B2 (en) | 2019-02-27 | 2025-01-16 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CA3131529A1 (en) | 2019-03-05 | 2020-09-10 | Amgen Inc. | Use of oncolytic viruses for the treatment of cancer |
| EP3938524A1 (en) * | 2019-03-14 | 2022-01-19 | Massachusetts Institute of Technology | Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof |
| TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
| JP7510952B2 (ja) | 2019-04-24 | 2024-07-04 | アムジエン・インコーポレーテツド | シリンジ滅菌確認アセンブリ及び方法 |
| AU2020337250A1 (en) | 2019-08-23 | 2022-03-03 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| WO2021127524A1 (en) * | 2019-12-20 | 2021-06-24 | Krystal Biotech, Inc. | Compositions and methods for gene delivery to the airways and/or lungs |
| WO2021216790A1 (en) | 2020-04-22 | 2021-10-28 | Indapta Therapeutics, Inc. | Natural killer (nk) cell compositions and methods for generating same |
| US20220016191A1 (en) * | 2020-07-16 | 2022-01-20 | Massachusetts Institute Of Technology | Simultaneous delivery of cancer treatment programs to tumor and immune cells |
| TW202241479A (zh) | 2020-12-30 | 2022-11-01 | 美商安迅生物製藥公司 | 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法 |
| WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| BR112023024278A2 (pt) | 2021-05-21 | 2024-01-30 | Amgen Inc | Método de otimizar uma receita de enchimento para um recipiente de fármacos |
| WO2023020598A1 (zh) * | 2021-08-20 | 2023-02-23 | 广东东阳光药业有限公司 | Hsv病毒载体及其应用 |
| EP4574169A1 (en) | 2022-08-16 | 2025-06-25 | Tomoki Todo | Pharmaceutical composition containing herpes simplex virus vector |
| WO2024251286A1 (zh) * | 2023-06-08 | 2024-12-12 | 上海药明生物医药有限公司 | 溶瘤性hsv-1临床分离株、定向进化株、感染性克隆及应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5163949A (en) * | 1990-03-02 | 1992-11-17 | Bonutti Peter M | Fluid operated retractors |
| US6610287B1 (en) | 1990-04-16 | 2003-08-26 | The General Hospital Corporation | Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
| GB9102126D0 (en) | 1991-01-31 | 1991-03-13 | Smithkline Beecham Biolog | Novel vaccine |
| GB9202933D0 (en) | 1992-02-12 | 1992-03-25 | Smithkline Beecham Biolog | Vaccines |
| DE69332525T2 (de) | 1992-03-31 | 2003-04-17 | Arch Development Corp., Chicago | Behandlung von Tumorerkrankungen mit modifiziertem HSV |
| GB9325496D0 (en) | 1993-12-14 | 1994-02-16 | Smithkline Beecham Biolog | Vaccines |
| US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
| GB9423663D0 (en) * | 1994-11-23 | 1995-01-11 | Cantab Pharma Res | Viral preparations, immunogens, and vaccines |
| NL9500216A (nl) * | 1995-02-06 | 1996-09-02 | Bio Pharma Sciences Bv | Farmaceutische samenstelling voor de behandeling van herpes. |
| WO1996026267A1 (en) * | 1995-02-21 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
| IL118942A (en) | 1995-07-27 | 2002-09-12 | American Cyanamid Co | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| US6344445B1 (en) * | 1995-10-19 | 2002-02-05 | Cantab Pharmaceutical Research Limited | Herpes virus vectors and their uses |
| GB9524973D0 (en) * | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| ATE241994T1 (de) | 1996-01-25 | 2003-06-15 | Univ Glasgow | Hsv-mutant-1716 zur behandlung von mesotheliomen |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| US5876923A (en) * | 1996-07-26 | 1999-03-02 | Arch Development Corporation | Herpes simplex virus ICP4 as an inhibitor of apoptosis |
| GB9615794D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
| GB2322130B (en) | 1997-02-13 | 2000-12-20 | Secr Defence | A vaccine against Simian Herpes B virus |
| GB9704046D0 (en) | 1997-02-27 | 1997-04-16 | Univ Leeds | Arrestable therapeutic |
| US6051428A (en) * | 1997-03-21 | 2000-04-18 | Sloan-Kettering Institute For Cancer Research | Rapid production of autologous tumor vaccines |
| US5998174A (en) * | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| AU3001799A (en) * | 1998-03-12 | 1999-09-27 | Trustees Of The University Of Pennsylvania, The | Producer cells for replication selective viruses in the treatment of malignancy |
| GB9810904D0 (en) | 1998-05-20 | 1998-07-22 | Univ London | Mutant herpes simplex viruses and uses thereof |
| US6713067B2 (en) * | 1998-07-31 | 2004-03-30 | Biovex Limited | Herpes viruses for immune modulation |
| GB9816781D0 (en) * | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| KR20010085348A (ko) | 1998-08-07 | 2001-09-07 | 추후보정 | 면역능을 갖는 헤르페스 심플렉스 바이러스 항원 및 이를이용하는 방법 |
| JP2003535565A (ja) * | 1998-12-31 | 2003-12-02 | アーチ ディベロプメント コーポレイション | 新生物疾患の治療に有用な組換え単純ヘルペスウイルス |
| US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US6764675B1 (en) * | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
| EP1190040B1 (en) | 1999-06-08 | 2007-08-22 | UAB Research Foundation | Herpes simplex virus expressing interleukin-12 gene and and its use for treating cancer |
| IL131212A0 (en) * | 1999-08-03 | 2001-01-28 | Yissum Res Dev Co | Recombinant virus and live-virus vaccines |
| GB9930419D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| GB9930418D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| BRPI0107736B8 (pt) | 2000-01-21 | 2021-05-25 | Biovex Ltd | cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1 |
| GB0001476D0 (en) | 2000-01-21 | 2000-03-15 | Neurovex Ltd | Herpes virus strains |
| US7063851B2 (en) * | 2000-04-12 | 2006-06-20 | Biovex Limited | Herpes viruses for immune modulation |
| GB0317511D0 (en) * | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| EP3400293B2 (en) * | 2016-01-08 | 2023-07-12 | Replimune Limited | Modified oncolytic virus |
-
2001
- 2001-01-22 BR BRPI0107736A patent/BRPI0107736B8/pt unknown
- 2001-01-22 CN CN01806743A patent/CN1418255A/zh active Pending
- 2001-01-22 ES ES01901292T patent/ES2254359T3/es not_active Expired - Lifetime
- 2001-01-22 BR BR0107736-8A patent/BR0107736A/pt not_active IP Right Cessation
- 2001-01-22 CA CA2398335A patent/CA2398335C/en not_active Expired - Lifetime
- 2001-01-22 WO PCT/GB2001/000225 patent/WO2001053505A2/en not_active Ceased
- 2001-01-22 AT AT01901288T patent/ATE282708T1/de active
- 2001-01-22 AU AU2695101A patent/AU2695101A/xx active Pending
- 2001-01-22 IL IL15067801A patent/IL150678A0/xx unknown
- 2001-01-22 JP JP2001553367A patent/JP4810042B2/ja not_active Expired - Lifetime
- 2001-01-22 DE DE60115600T patent/DE60115600T2/de not_active Expired - Lifetime
- 2001-01-22 CA CA002398343A patent/CA2398343A1/en not_active Abandoned
- 2001-01-22 DK DK01901292T patent/DK1252323T3/da active
- 2001-01-22 EP EP01901288A patent/EP1252322B2/en not_active Expired - Lifetime
- 2001-01-22 WO PCT/GB2001/000229 patent/WO2001053506A2/en not_active Ceased
- 2001-01-22 ES ES01901288T patent/ES2233600T5/es not_active Expired - Lifetime
- 2001-01-22 EP EP05011798A patent/EP1568779A1/en not_active Ceased
- 2001-01-22 DE DE60107203T patent/DE60107203T3/de not_active Expired - Lifetime
- 2001-01-22 AT AT01901292T patent/ATE312189T1/de active
- 2001-01-22 KR KR1020027009412A patent/KR100768408B1/ko not_active Expired - Lifetime
- 2001-01-22 HK HK02108740.4A patent/HK1047297B/zh unknown
- 2001-01-22 HK HK02108579.0A patent/HK1047451B/zh unknown
- 2001-01-22 US US10/181,692 patent/US7063835B2/en not_active Expired - Lifetime
- 2001-01-22 JP JP2001553368A patent/JP4921669B2/ja not_active Expired - Lifetime
- 2001-01-22 AU AU2001226951A patent/AU2001226951B8/en active Active
- 2001-01-22 CN CNB018067506A patent/CN1250732C/zh not_active Expired - Lifetime
- 2001-01-22 GB GB0219030A patent/GB2375113B/en not_active Expired - Lifetime
- 2001-01-22 EP EP01901292A patent/EP1252323B1/en not_active Expired - Lifetime
- 2001-01-22 GB GB0219033A patent/GB2374873C/en not_active Expired - Lifetime
- 2001-01-22 IL IL15067701A patent/IL150677A0/xx unknown
- 2001-01-22 EP EP09014990A patent/EP2177619A1/en not_active Withdrawn
- 2001-01-22 BR BRPI0107737A patent/BRPI0107737B8/pt not_active IP Right Cessation
- 2001-01-22 DK DK01901288T patent/DK1252322T4/da active
- 2001-01-22 PT PT01901288T patent/PT1252322E/pt unknown
- 2001-01-22 KR KR1020027009410A patent/KR100802403B1/ko not_active Expired - Lifetime
- 2001-01-22 US US10/181,697 patent/US7223593B2/en active Active
-
2002
- 2002-07-10 IL IL150677A patent/IL150677A/en active Protection Beyond IP Right Term
- 2002-07-10 IL IL150678A patent/IL150678A/en not_active IP Right Cessation
-
2006
- 2006-03-10 US US11/372,613 patent/US7537924B2/en not_active Expired - Lifetime
-
2007
- 2007-04-23 US US11/738,807 patent/US8277818B2/en not_active Expired - Fee Related
-
2009
- 2009-04-17 US US12/425,952 patent/US20090220460A1/en not_active Abandoned
-
2011
- 2011-10-31 JP JP2011238257A patent/JP2012072156A/ja active Pending
-
2012
- 2012-02-17 US US13/399,868 patent/US20120164108A1/en not_active Abandoned
- 2012-08-31 US US13/600,711 patent/US8680068B2/en not_active Expired - Fee Related
-
2014
- 2014-02-06 US US14/174,521 patent/US20140154215A1/en not_active Abandoned
- 2014-02-07 US US14/175,855 patent/US10301600B2/en not_active Expired - Fee Related
-
2015
- 2015-04-29 US US14/700,036 patent/US20150232812A1/en not_active Abandoned
- 2015-07-10 JP JP2015138227A patent/JP6424145B2/ja not_active Expired - Lifetime
-
2016
- 2016-06-08 LU LU93100C patent/LU93100I2/fr unknown
- 2016-06-08 LU LU93101C patent/LU93101I2/fr unknown
- 2016-06-14 NL NL300820C patent/NL300820I2/nl unknown
- 2016-06-14 NL NL300821C patent/NL300821I2/nl unknown
- 2016-06-14 BE BE2016C033C patent/BE2016C033I2/fr unknown
- 2016-06-15 FR FR16C0026C patent/FR16C0026I2/fr active Active
- 2016-06-15 CY CY2016020C patent/CY2016020I1/el unknown
- 2016-06-15 CY CY2016021C patent/CY2016021I2/el unknown
-
2017
- 2017-03-01 JP JP2017037827A patent/JP2017132779A/ja active Pending
-
2018
- 2018-11-22 JP JP2018218735A patent/JP6644378B2/ja not_active Expired - Lifetime
-
2019
- 2019-04-02 US US16/372,800 patent/US20200032218A1/en not_active Abandoned
- 2019-04-05 US US16/376,089 patent/US20200032219A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100768408B1 (ko) | 헤르페스 바이러스 주 | |
| AU2004261037B2 (en) | Viral vectors | |
| AU2001226951A1 (en) | Virus strains for the oncolytic treatment of cancer | |
| HK1083595B (en) | Viral vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20020722 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20051209 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20061115 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20070726 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20071012 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20071012 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| G170 | Re-publication after modification of scope of protection [patent] | ||
| PG1701 | Publication of correction | ||
| PR1001 | Payment of annual fee |
Payment date: 20101012 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110830 Start annual number: 5 End annual number: 5 |
|
| J202 | Request for trial for correction [limitation] | ||
| PJ0202 | Trial for correction |
Comment text: Request for Trial Patent event date: 20111026 Patent event code: PJ02022R01D Comment text: Registration of Establishment Patent event date: 20071012 Patent event code: PJ02021E01I Appeal kind category: Correction Decision date: 20120531 Request date: 20111026 Appeal identifier: 2011105000093 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20111026 Effective date: 20120531 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S03D Patent event date: 20120531 Comment text: Trial Decision on Correction (Patent, Utility Model) Appeal kind category: Correction Request date: 20111026 Decision date: 20120531 Appeal identifier: 2011105000093 |
|
| FPAY | Annual fee payment |
Payment date: 20120924 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120924 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20130926 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130926 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20140923 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140923 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20150918 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150918 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20160921 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160921 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20170919 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170919 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180918 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200928 Start annual number: 14 End annual number: 14 |
|
| PC1801 | Expiration of term |
Termination date: 20210722 Termination category: Expiration of duration |